Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration

This trial tests abemaciclib — a drug already approved for breast cancer — in patients with bone or soft tissue sarcomas whose tumors have a specific molecular defect (overexpression of CDK4 or amplification of the CDK4 gene). The idea is that the same molecular vulnerability found in breast cancer may exist in some sarcomas. **You may be eligible if...** - You have a bone or soft tissue sarcoma that has spread or cannot be surgically removed - Your tumor shows CDK4 overexpression or CDK4 gene amplification on testing - You have received at least one prior line of therapy - You are 18 or older and in adequate general health **You may NOT be eligible if...** - Your tumor does not have CDK4 amplification or overexpression - You have had too many prior lines of therapy (specific limits apply) - You have serious heart problems or other significant medical conditions - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.